Paul Reider has followed Coherus BioSciences’ last biosimilar product out the door. | Paul Reider has followed Coherus ...

India's pharma and healthcare sector demonstrates resilient investor interest, marked by a 34% year-on-year increase in deal ...

DelveInsight's "Uterine Sarcoma Market Insights, Epidemiology, and Market Forecast- 2032" report delivers an in-depth ...

Dr. Kiran Mahasuar, Asst Professor at IMT Ghaziabad, writes why branded generics may still dominate volumes, but the real ...

Ahmedabad: Intas Pharma has announced the appointment of Sarang Pande as Vice President - Digital Manufacturing & Industry ...

Coherus BioSciences has completed the sale of its Udenyca (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals under an ...

Among top donors to major parties, at least five companies are facing probes by central agencies, of which four have donated ...

– Coherus to focus exclusively on its innovative novel oncology programs including: – LOQTORZI®, a revenue-generating and differentiated PD-1 inhibitor; – Casdozokitug, a first-in-class interleukin-27 ...

Shares of California-based Coherus BioSciences (Nasdaq: CHRS) rose more than 5% to $0.88 in pre-market activity today as it ...

Intas Pharmaceuticals has completed its acquisition of the UDENYCA (pegfilgrastim-cbqv) business from Coherus BioSciences Inc ...

Coherus BioSciences (CHRS) announced the completion of the previously announced divestiture of its UDENYCA franchise to Intas Pharmaceuticals ...

President Donald Trump says he plans to impose tariffs on pharmaceuticals "very shortly," in what could be the next phase of his sweeping overhaul of global trade. President Donald Trump says he ...